Iproniazid

Structural formula
General
Non-proprietary name	Iproniazid
other names	N '-Isopropyl-isonicotinohydrazide; N ′ -propan-2-ylpyridin-4-carbohydrazide ( IUPAC );
Molecular formula	C 9 H 13 N 3 O
External identifiers / databases
ECHA InfoCard	100,000,199
PubChem	3748
DrugBank	DB04818
Wikidata	Q421368
Drug information
ATC code	N06 AF05
Drug class	Antidepressants
Mechanism of action	MAOIs
properties
Molar mass	179.22 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302
	P: ?
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Iproniazid is as antidepressant used hydrazine derivative . It is an irreversible, non-selective inhibitor of monoamine oxidase ( MAOIs ). Even if it is rarely used in most parts of the world, it is still used in France .

history

Iproniazid was the first antidepressant to be marketed. However, it was originally developed as a remedy for tuberculosis . Its antidepressant properties were discovered in 1952 when researchers found that patients treated with iproniazid were becoming "unusually cheerful." It was approved as an antidepressant in 1958, but withdrawn from the market in 1961 after cases of hepatitis occurred and replaced by less hepatotoxic substances such as isocarboxazid , phenelzine and tranylcypromine . An important researcher in the field of the first antidepressants in the United States was Nathan S. Kline .

Individual evidence

↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of iproniazid in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on July 6, 2020, is reproduced from a self-classification by the distributor .
↑ ^a ^b ^c ^d ^e Robert A. Maxwell, Shohreh B. Eckhardt: Drug discovery . Humana Press, 1990, ISBN 0-89603-180-2 , pp. 143-154 (455 pp.).
↑ Fagervall I, Ross SB: Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors . In: Biochemical pharmacology . 35, No. 8, April 1986, pp. 1381-1387. doi : 10.1016 / 0006-2952 (86) 90285-6 . PMID 2870717 .
^ Bangen, Hans: History of the drug therapy of schizophrenia. Berlin 1992, ISBN 3-927408-82-4 , page 91.

[1] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of iproniazid in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on July 6, 2020, is reproduced from a self-classification by the distributor .

[bookDrug_discovery-2] Robert A. Maxwell, Shohreh B. Eckhardt: Drug discovery . Humana Press, 1990, ISBN 0-89603-180-2 , pp. 143-154 (455 pp.).

[pmid2870717-3] Fagervall I, Ross SB: Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors . In: Biochemical pharmacology . 35, No. 8, April 1986, pp. 1381-1387. doi : 10.1016 / 0006-2952 (86) 90285-6 . PMID 2870717 .

[4] Bangen, Hans: History of the drug therapy of schizophrenia. Berlin 1992, ISBN 3-927408-82-4 , page 91.